bpV (HOpic) Clinical Trials

Size	Price	Qty
5mg	USD 147
25mg	USD 470

Clinical Trials

Multiple clinical trials are currently investigating this compound across Phase 1, Phase 2, and Phase 4 protocols for indications including multiple myeloma, obstructive sleep apnea, blood pressure variability, and primary total knee arthroplasty. Predominantly sponsored by academic and medical institutions, such as University Hospital Heidelberg, National Jewish Health, Cedars-Sinai Medical Center, and Wake Forest University Health Sciences, these investigations feature recruitment statuses ranging from completed studies to protocols that are not yet recruiting.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07097493	NOT_YET_RECRUITING	Knee Arthroplasty, Total	Wake Forest University Health Sciences	2027-02	PHASE4
NCT06012487	NOT_YET_RECRUITING	Blood Pressure Variability	Cedars-Sinai Medical Center	2026-05-01	PHASE1
NCT02314858	COMPLETED	Obstructive Sleep Apnea (OSA)	National Jewish Health	2014-10-01
NCT02237261	COMPLETED	Multiple Myeloma	University Hospital Heidelberg	2014-11	PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-25)

Check the bpV (HOpic) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As a potent inhibitor of PTEN with an IC50 of 14 nM, bpV (HOpic) selectively binds the PTEN active site and suppresses its lipid phosphatase activity, thereby blocking the conversion of phosphatidylinositol 3,4,5-trisphosphate to phosphatidylinositol 4,5-bisphosphate and increasing intracellular levels of PIP3. This accumulating PIP3 triggers constitutive downstream AKT phosphorylation and cellular survival signaling, which alters growth regulatory phenotypes and provides mechanistic context for target modulation in conditions such as multiple myeloma.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).